SMIL is taking advanced precautions to guard against Coronavirus - learn more before arriving at one of our facilities. Click here.
Arizona requires notification be provided to women with dense breast tissue following their mammogram. Patients turn to both women's imaging specialists and to their own health care providers for explanation and answers.
DenseBreast-info.org is an information resource for both health care professionals and patients. It is supported by the 501-c-3 non-profit, DenseBreast-info, Inc
Learn more http://densebreast-info.org/dense-breast-information-for-health-professionals.aspx
Calculations for the patient's five-year and lifetime breast cancer risk are given in the SMIL radiology report. These include:
Each model has unique thresholds describing Average, Intermediate and High Risk:
Today, there's no clear solution. Some healthcare providers and organizations recommend annual screening for women starting at 40, and others recommend screening every other year starting at 50. Wait until women turn 50 to start screening, and you'll reduce the number of false alarms— but you'll also miss some cases of cancer. Screen every other year, and you face the same risks. So what's the answer?
Part of the answer is that every woman is unique. We have different risk factors, different genetic makeups, different family histories. Identifying high-risk patients will result in even better patient care. Working in concert with the patients' primary care providers, radiologists can identify and recommend increased surveillance for those patients who are at high risk.
SMIL Imaging centers are using MRS (Mammography Reporting Systems) to provide the underlying technology. By capturing individualized risk data in real time, healthcare providers can make impactful decisions about each individual's health care, rather than using broad assumptions to provide generalized care. That's what the whole precision medicine idea is about: tailoring the approach for each individual.
MRS is the leading provider of breast procedure information systems in the United States and the most widely used breast procedure reporting and tracking system in the world.
MRS software includes the ability to alert healthcare professionals when a patient's personal or family history indicates they may be at higher risk for breast cancer, consistent with professional society guidelines.
The Tyrer Cuzick 10 Year and Tyrer Cuzick Lifetime models utilize the following factors:
No calculations will be generated for the following reasons:
The Myriad BRCA Prevalence Table is a risk model that has been provided by Myriad Genetics, Inc. -the organization which patented the BRCA gene mutation test.
It provides the prevalence of BRCA1 and BRCA2 mutations based on:
The Myriad Table utilizes the following Personal Cancer History:
And the following Family Cancer History:
The Gail 5 Year & NCI Lifetime Models utilize the following factors:
No calculations will be generated for the following reasons:
There are multiple breast cancer risk models but none are perfect. Each uses different groups of presumed breast cancer risk factors to make an estimate and results may vary from model to model due to differences in the factors taken in to account. The factors fall in three basic categories: hereditary, hormonal, and pathologic. The risk of breast cancer over time can help provide guidance for different management plans such as earlier (or later) mammography, risk-based screening, adding MRI, or the need for chemoprevention. The risk of mutation can help determine the need for genetic testing.
Because most of the studies showing the benefits of breast MRI have been based on screening women at high risk due to family history and/or genetic mutations, both the ACS and ACR recommend annual breast MRI in conjunction with annual mammography for women with a lifetime risk of breast cancer of 20-25% or greater using a model based mainly on family history such as Tyrer Cuzick.